Markets and Recent Developments in Medical Technologies, from MedMarket Diligence, LLC

Rapid Growth in Asia-Pacific Spine Surgery Technology Markets

patrick@mediligence.com — Wed, 1 Oct 2008 12:22:52 -0700

The Asia-Pacific spine surgery market is growing rapidly, at an estimated compound annual growth rate of 18%. The market is therefore expected to more than quadruple in size by the end of the forecast period.

The advanced medical technologies blog highlights the market for spine surgery products and technologies in Japan, Korea and Australia, drawn from the 2008 report, "Worldwide Spine Surgery 2008-2017," report #M510, published by MedMarket Diligence.

Energy-Based Device Markets: Ablation Technologies, Share by Segment and Country/Region

patrick@mediligence.com — Thu, 25 Sep 2008 21:22:15 -0700

The worldwide high energy therapies market represents a $25 billion opportunity in 2008. The category consists of therapeutic devices and equipment that deliver the controlled application of one or more modalities of energy to tissue. The worldwide market for ablation and other energy-based technologies is the subject of a new market and technology report, "Ablation Technologies Worldwide Market, 2008-2017: Products, Technologies Markets, Companies and Opportunities", from MedMarket Diligence, LLC . The report details the products on the market, products in development and analysis of the market by technology (electrical, radiation, light, radiofrequency, cryotherapy, thermal, microwave, and hydromechanical) and by country/region: Americas (USA, Canada, Mexico, Brazil), Europe (Germany, United Kingdom, France, Italy, Spain, BeNeLux), Asia/Pacific (Japan, China, India, Australia) and Rest of World.

The report is described detail, with table of contents and list of exhibits, here.

The report may be ordered online here or via order form attached (also here).

Ablation Technologies and Other Energy-Based Therapies Proliferating Worldwide

patrick@mediligence.com — Fri, 12 Sep 2008 15:38:13 -0700

The global market for ablation and other energy-based therapeutics is swelling at double digit growth rates, with revenues in some energy types growing at or beyond 20% annually. The efficacy of different modalities in achieving different clinical end-points (cutting, coagulating, excising tissue, creating anti-arrhythmic lesions, etc.) is increasing with new product developments and products are being more readily adopted by clinicians becoming facile with their use. The worldwide market for ablation and other energy-based technologies is the subject of a new market and technology report, "Ablation Technologies Worldwide Market, 2008-2017: Products, Technologies Markets, Companies and Opportunities", from MedMarket Diligence, LLC

The report is described detail, with table of contents and list of exhibits, here.

Wound Management Market Segment Growth, 2008-2017

patrick@mediligence.com — Sat, 23 Aug 2008 08:00:13 -0700

Technologies developed and in use for the management of acute and chronic wounds have diversified from traditional dressings, bandages and wound closure techniques to include an increasing number of diverse technologies ranging from tissue engineering, growth factors, physical therapies (e.g., negative pressure) and others. Traditional dressings and bandages have evolved to contain more active elements contributing to wound healing, with products including films, hydrocolloids, foams, alginates, hydrogels, non-adherents and antimicrobials.
The advanced medical technologies blog details the different segment growth rates within the worldwide wound management market.

Wound management is the focus of the comprehensive MedMarket Diligence report #S245, "Worldwide Wound Management, 2007-2016". See link for details.

Spine fusion companies, by technology

patrick@mediligence.com — Fri, 22 Aug 2008 10:58:38 -0700

Surgeons performing instrumented spinal fusion procedures implant various configurations of plates, rods, screws, cages, and other medical hardware to stabilize the spine and facilitate proper vertebral bone fusion. Recent blog "advanced medical technologies" details spine fusion technologies and active companies, by technology.

Spine surgery (worldwide) is also the subject of a 2008 report from MedMarket Diligence, See link for description and table of contents.

Ablation: An Energized Market

patrick@mediligence.com — Tue, 19 Aug 2008 08:15:32 -0700

Energy-based therapies generate sales of $13 billion in the United States alone, with probably another $12 billion in other developed markets worldwide. This represents around 13% of the total medical device market, and it is growing at 11% per annum --- twice the growth rate for medical devices overall.

Ablation and other energy-based technologies are discussed in recent mediligence.com/blog posts.

Ablation is the subject of a forthcoming report from MedMarket Diligence, "Ablation Technologies Worldwide Market." See link for description and table of contents.

Top Line Market Data Released in Selected Executive Summaries from MedMarket Diligence Reports

patrick@mediligence.com — Fri, 13 Jun 2008 08:07:09 -0700

MedMarket Diligence (MMD) is now making available the executive summaries -- top line data on products, technologies, companies, markets, and opportunities -- from selected MMD Reports:

Spine Surgery Worldwide 2008-2017. See link for full report details.
Ophthalmology 2007 Worldwide. See link for full report details.
Wound Management Worldwide 2007-2016. See link for full report details.
Obesity Management Worldwide 2007. See link for full report details.
Diabetes Worldwide 2005-2015. See link for full report details.

For ordering any of these executive summaries, go to link. For additional details, contact Patrick Driscoll at (949) 859-3401 or patrick mediligence com.

Spine Surgery Steadily Adopting Minimally Invasive Procedures (MedMarket Diligence Report)

patrick@mediligence.com — Fri, 6 Jun 2008 08:25:29 -0700

The development of imaging systems like fluoroscopy, sophisticated endoscopes and a wide range of surgical instruments that facilitate minimally invasive surgery are combining with the persistent demand for less invasive, less traumatic procedures to drive the growth of minimally invasive spine surgery. Products, technologies and trends in minimally invasive surgery are detailed in the worldwide spine surgery report from MedMarket Diligence.

The report #M510 on "Spine Surgery Worldwide" is described, with complete table of contents and list of exhibits, at link.

Tags: spine, degenerative disc, interbody fusion, artificial disc

Obesity: Products, Technologies, Markets and Companies in the Clinical Management of Obesity Worldwide (MMD Report)

patrick@mediligence.com — Thu, 29 May 2008 15:07:53 -0700

Technologies for the management of obesity span surgical approaches, medically supervised diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. MedMarket Diligence's global analysis of the caseload, incidence/prevalence, clinical practice trends, products in development and on the market, current/forecast market, competitor shares and company profiles is a detailed and valuable framework for any current or potential medtech innovator seeking to compete in the worldwide market for the clinical management of obesity.

The report is described, with full table of contents and list of exhibits, here.

The report can also be ordered online here.

Tags: obesity, bariatric,

Opportunities in wound closure, hemostasis and anti-adhesion, worldwide

patrick@mediligence.com — Thu, 29 May 2008 14:30:57 -0700

Significant opportunities for products in wound closure, hemostasis and anti-adhesion products continue to be available for established and emerging companies, driven by innovation in the products themselves and penetration of more caseload, including growth in more medical and surgical specialties. The market for these products is also growing through their expansion globally, with products being introduced and finding clinical acceptance in the U.S., Europe, Central and South America elsewhere in the world.

The applications, products, technologies and markets are also the subject of a definitive MedMarket Diligence report, "Worldwide Sealants, Glues & Wound Closure, 2007-2011."

The report is described, with full table of contents and list of exhibits, here.

The report can be ordered online here.

See also the 2007 report, "Worldwide Wound Management, 2007-2016," with detailed table of contents and list of exhibits, here.

Sealants, Glues, Hemostasis, and Securement Uses Support Intense Competitive Activity and Accelerated Market Growth

patrick@mediligence.com — Wed, 28 May 2008 11:43:45 -0700

The applications and the benefits of medical/surgical sealants, hemostatics, closure and anti-adhesion are discussed in a recent post on the advanced medical technologies blog.  These benefits are the reason behind intense competitive interest and the accelerated market growth of these products.

The applications, products, technologies and markets are also the subject of a definitive MedMarket Diligence report, "Worldwide Sealants, Glues & Wound Closure, 2007-2011."

The report is described, with full table of contents and list of exhibits, here.

The report can be ordered online here.

Medical and Surgical Glues, Sealants, Hemostasis and Wound Closure by Region/Country

patrick@mediligence.com — Fri, 16 May 2008 10:29:02 -0700

Medical and surgical glues, sealants, hemostasis and wound closure products, products under development, current/forecast market and market shares and other data and insights reveal opportunities in these markets globally through the 2007 MedMarket Diligence report, "Wordwide Surgical Sealants, Glues and Wound Closure 2007."  Caseload volumes, current markets globally (by region and country), new product development status detail, local/regional clinical practice trends, competitor shares and other hard data reveal opportunities in the worldwide market.  This report has become a definitive source of data and insights for leading and emerging contenders in the markets for sealants/glues/wound closure.

Products covered:  Sutures and staples, tapes, hemostats, fibrin and sealant products and medical adhesives.

Geographic detail:  U.S., Europe (United Kingdom, German, France, Italy, BeNeLux), Latin America, Japan and Rest of World

The report is described, with full table of contents and list of exhibits, here.  The report can be ordered online here.

"Worldwide Wound Management 2007-2016" MedMarket Diligence

patrick@mediligence.com — Thu, 8 May 2008 10:00:49 -0700

Products in wound management span simple dressings and bandages to advanced biotech, mechanical and other technologies designed to facilitate and accelerate the wound healing process. The combined nature of the resulting product market -- from well established high volume sectors to rapid growth emerging sectors -- represents enormous business potential for current and prospective wound management companies. MedMarket Diligence's report, "Worldwide Wound Management 2007-2016", publishing November 2007, details the products, technologies, markets and companies worldwide in the wound management industry.

The report is described, with full table of contents and list of exhibits, here.

The report can be ordered online.

Tags: wound

Spine Surgery Worldwide Market Characterized by Many New Technologies, Changing Clinical Practice Dynamics and Double Digit Growth, According to New Report from MedMarket Diligence, LLC

patrick@mediligence.com — Tue, 6 May 2008 15:41:22 -0700

Among the most device-intensive healthcare markets, the spine surgery market has been undergoing dramatic changes as numerous new technologies take hold in the well established spine surgery surgical arena and manufacturers continue to develop new technologies and roll them out for a growing patient population. Globally, the market will grow to over $26 billion over the next ten years, demonstrating double digit growth in the process. A new report from MedMarket Diligence, "Spine Surgery: Products, Technologies, Markets & Opportunities, Worldwide, 2008-2017", details the products, technologies, markets and companies worldwide.

The report is described, with full table of contents and list of exhibits, here.

The report can be ordered online.

Tags: spine, degenerative disc, interbody fusion, artificial disc

Key Facts in the Worldwide Spine Surgery Market

patrick@mediligence.com — Wed, 30 Apr 2008 13:01:06 -0700

Striking facts about the worldwide spine surgery market, covered in report #M510 from MedMarket Diligence, LLC:

Seven of eight technology market segments within spine surgery show double-digit compound growth rates through 2017.

Three (almost four) of the eight technology market segments within spine surgery show compound growth rates in excess of 20% through 2017

The U.S. accounts for 76% of the worldwide spine surgery market

At least 38 companies have been founded in the spine surgery arena since 2002.

Spine Surgery Worldwide Report: Robust and Growing List of Companies Active in Spine Surgery According to New Report from MedMarket Diligence, LLC

patrick@mediligence.com — Mon, 31 Mar 2008 13:10:25 -0700

Companies active in the marketing and development of spine surgery technologies have grown in number in recent years as the growing caseload, expanding capabilities of new techniques and technologies, and the rapid adoption by spine surgeons are driving attractive market growth for current and hopeful market competitors.
Companies in spinal technology market development and address in the MedMarket Diligence report #M510 include the following:

Abbott Spine, Alphatec Holdings, Inc., Anulex Technologies, Inc., Applied Spine Technologies, A-Spine Holding Group Corporation, AxioMed Spine Corporation, BioAssets Development Corporation, Biorthex, Inc., BrainLAB, Cervitech, Co.Don AG, Cook Group, Corin Group, Cryolife, Inc., Cytori Therapeutics, Disc Dynamics, Encore Medical Corporation, Fixano, Gentis, Inc, GMReis, Innovative Spinal Technologies, Integra Radionics, Interventional Spine, LDR Holding Corporation, Mazor Surgical Technologies Ltd, Medtronic Sofamor Danek, Mekanika, Inc., MiMedx, MTF (Musculoskeletal Transplant Foundation), N Spine, Inc. (Synthes), Ortho Development Corporation, OrthoVita, Osteotech, Inc., Paradigm Spine, LLC, Praxim, Raymedica, Inc., Scient’X, Sharma Surgical, Smart Disc, SpinalMotion, Spineology, SpineVision Inc, Stryker Corporation, Stryker Spine, Theken Spine, Trimedyne, Inc., Valleylab, Waston Medical, X-spine Systems, Inc., AlloSource, Altiva Corporation, ApaTech, ArthroCare Corporation, Axial Biotech, B. Braun/Aesculap, Inc., Biomet, Blackstone Medical, Inc, Cardinal Health, Changzhou Kanghui, CoLigne AG, CoreSpine Technologies LLC, Cortek, Inc, Cyberkinetics Neurotechnology Systems, DePuy Spine/J&J, Disc Motion Technologies, Facet Solutions, GE Healthcare, Globus Medical, HydroCision, Integra LifeSciences, Interpore Cross, Invibio, LifeNet Health, Inc., Medtronic, Inc, Medtronic Surgical Navigation, Merck & Co., Inc., Misonix, NPS Pharmaceuticals, NuVasive, Inc., Orthofix International, N.V., Osiris Therapeutics, Ortosintese, Pitkar, Ranier Technology Limited, Regeneration Technologies, Inc, SeaSpine, Inc., Small Bone Innovations, LLC, Smith & Nephew, SpineMedica Corporation, SpineOvations, Spine Wave, Inc., Stryker Instruments, Synthes Spine Solutions, TranS1, Inc., Ulrich Medical GmbH, Vertebron Inc., Wright Medical Technology, Zimmer Spine

Worldwide Spine Surgery Market Characterized by Many New Technologies, Dynamics and Double Digit Growth, According to New Report from MedMarket Diligence, LLC

patrick@mediligence.com — Wed, 12 Mar 2008 15:59:26 -0700

Wound Types and Advanced Wound Products, Worldwide (MedMarket Diligence report #S245)

patrick@mediligence.com — Mon, 7 Jan 2008 11:39:59 -0800

The worldwide wound management market stood at $4.6 billion in 2007 and will reach $11.5 billion by 2016. As one of the most technologically diverse areas of medicine, products in wound management span simple dressings and bandages to advanced biotech, mechanical and other technologies designed to facilitate and accelerate the wound healing process. The combined nature of the resulting product market -- from well established high volume sectors to rapid growth emerging sectors -- represents enormous business potential for current and prospective wound management companies. MedMarket Diligence's report, "Worldwide Wound Management 2007-2016: Established and Emerging Products, Technologies and Markets in the U.S., Europe, Japan and Rest of World", published November 2007, details the products, technologies, markets and companies worldwide in the wound management industry.

The report is described, with full table of contents and list of exhibits, here.

The report can be ordered online.

Tags: wound

Published: "Worldwide Wound Management 2007-2016" New Report from MedMarket Diligence

patrick@mediligence.com — Mon, 26 Nov 2007 13:12:06 -0800

Worldwide Wound Management 2007-2016: New Report from MedMarket Diligence

patrick@mediligence.com — Thu, 8 Nov 2007 08:51:17 -0800

Drugs and Devices in the Clinical Management of Obesity Worldwide; New Report from MedMarket Diligence, LLC

patrick@mediligence.com — Thu, 20 Sep 2007 13:10:15 -0700

As the growing worldwide problem of obesity becomes more evident, including its commensurate healthcare costs, there is a coinciding proliferation of the number and type of approaches to address the problem. Clinical practices, products, technologies, companies and markets worldwide in the clinical management of obesity are detailed in a newly published report from MedMarket Diligence, "Worldwide Market for the Clinical Management of Obesity, 2007-2015."

The report is described, with full table of contents and list of exhibits, here.

The report can be ordered online.

Tags: obesity, bariatric, lapband

Obesity Drug and Device Markets Matching Growth in Obesity Prevalence

patrick@mediligence.com — Fri, 31 Aug 2007 14:03:06 -0700

The numbers in the obesity population continue to go grow and, with the aggressive development by manufacturers of myriad drug, device and other solutions to the clinical problem, the market for these products is matching that growth. The current clinical practices, procedures, products and their associated markets are the subject of a new analysis by MedMarket Diligence, "Worldwide Market for the Clinical Management of Obesity, 2007."

The report is described, with full table of contents and list of exhibits, here.

The report can also be ordered online here.

Tags: obesity, bariatric, lapband

Over 500 Medtech Startup Companies Identified

Tue, 4 Sep 2007 21:55:39 -0700

Over 500 companies represented in the Medtech Startup Companies Database from MedMarket Diligence comprise a robust range of new technologies --- and offer many opportunities for technology licensing, joint venture, investment and acquisition. Technologies under development include medical devices, diagnostics, drugs, biomaterials and others.

The database is described here.

For additional details, contact Patrick Driscoll of MedMarket Diligence, LLC. Tel: (949) 859-3401.

Tags: medtech, startups

Global Statistics on Incidence, Prevalence in Ophthalmology; Country-Specific Markets Xand Competitor Shares

Tue, 31 Jul 2007 11:01:14 -0700

Worldwide Ophthalmology Market 2007
A report with worldwide scope from MedMarket Diligence details the incidence and prevalence in ophthalmology, with country-specific detail worldwide for vision disorders, keratoconus, glaucoma, cataract and retinal disorders. Based on primary and secondary research among clinicians, manufacturers and other market stakeholders worldwide, the report provides extensively detailed incidence, prevalence, market size, growth, and forecasted competitor shares per country and/or region for the United States, individual western European countries (UK, Germany, France, BeNeLux, Italy and Spain), Japan and other key international markets; Asia (India, Korea, Australia, Russia and China), other Americas (Canada, Mexico, Brazil) and Middle East and Africa categories.

The report is described with a detailed table of contents and list of exhibits here. The report is available for purchase online here.

Tags: medtech, ophthalmology

Medical Technology Takes Turn Toward Hybrids, Increased Performance

Wed, 25 Jul 2007 15:10:06 -0700

If the types of technologies that are now under development at new medical technology startups are any indication, manufacturers are increasingly turning toward the addition of technologies that are complementary to devices in order to achieve gains in product performance.

New medical technologies under development at startups founded within the past 12 month shows the use of multiple different technologies to achieve improved clinical outcomes.

Companies and their technologies have been identified by MedMarket Diligence and are accessible via the Medtech Startups Database.

Tags: medtech, startups

Obesity 2007: Worldwide Market for the Clinical Management of Obesity, report from MedMarket Diligence, LLC

Sat, 7 Jul 2007 11:43:34 -0700

The clinical management of obesity represents a worldwide market --- encompassing devices, surgical procedures, drugs and other therapies --- that will surpass $5 billion by 2013. MedMarket Diligence has closely tracked this market and will release its 2007 analysis of the worldwide market for products in the clinical management of obesity.

Products to manage clinical obesity span surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. The MedMarket Diligence report describes clinical trends in the management of the obese. The report details the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy, and provides current and forecast of the market for these products in the U.S., Europe and Rest of World. The report profiles key companies in the market, detailing the current products, products in development, market position and overall businesses in obesity management.

The Worldwide Market for the Clinical Management of Obesity, 2007 is described with table of contents at http://www.mediligence.com/rpt/rpt-s825.htm. The report may be ordered here or via order form.

Tags: medtech, obesity

See complete MMD report listing here.

(UPDATE) Medtech Startup Companies Database (Nearly 500 Companies) now available from MedMarket Diligence, LLC

info@mediligence.com — Fri, 22 Jun 2007 10:43:33 -0700

MedMarket Diligence has introduced a new online database of startup medtech companies. Drawn from the ongoing research performed in support of the MedMarkets newsletter and market and technology Reports, the Medtech Startups Database is an online, boolean searchable database of new medical product companies spanning medical device, biotech, biomaterials, biopharm, and others competing in these often overlapping market.

The database, currently comprised of nearly 500 recent medtech startups, is updated each month with roughly 10 recently founded companies. Records on existing companies in the database are also reviewed on a regular basis to update company data. The companies in this database represent companies reported in the MedMarkets publication, with details as complete as possible on these frequently "stealth" companies, but also include other companies separately identified by MedMarket Diligence through its proprietary report and other research activities. Companies included span the medical device, biotech, biomaterial, pharmaceutical and other areas.

The Medtech Startups Database is an online database available through annual subscription options.

See http://www.mediligence.com/startups-db.htm for more details.

Tags: medtech, startups

See complete MMD Market and Technology Reports listing here.

Medical/Surgical Glues and Sealants Have Firm Hold on Applications

Mon, 11 Jun 2007 13:27:41 -0700

A robust array of medical/surgical sealants, glues, and hemostatic agents are progressively taking hold of significant shares of caseload spanning many different clinical applications, from cardiovascular to orthopedic, neurological, urological, skin/integumentary, plastic surgery/aesthetics, and others. Products, technologies, indications, current/potential caseload and companies are detailed in the MedMarket Diligence report, "Worldwide Surgical Sealants, Glues and Wound Closure 2007."

Opportunities for products in wound closure, hemostasis and anti-adhesion products continue to be available for established and emerging companies, driven by innovation in the products themselves and penetration of more caseload, including growth in more medical and surgical specialties. The market for these products is also growing through their expansion globally, with products being introduced and finding clinical acceptance in the U.S., Europe, Central and South America elsewhere in the world.

See the full MedMarket Diligence report, with description and table of contents at http://www.mediligence.com/rpt/rpt-s145.htm.

Worldwide Surgical Sealants, Glues and Wound Closure 2007 may be purchased here.

Tags: medtech, hemostats, sealants

See complete MMD report listing here.

Report: Worldwide Surgical Sealants, Glues and Wound Closure 2007 Market

Fri, 11 May 2007 12:27:32 -0700

MedMarket Diligence has tracked the emergence and growth of novel technologies in wound closure, hemostasis and anti-adhesion over the past decade, providing insight into market introduction, growth, competition and opportunity through worldwide analysis. The products, markets and companies in this medical technology arena have now been analyzed in the detailed report from MedMarket Diligence. The 2007 report reveals the markets worldwide, with detailed forecasts of geographic segmentation, for surgical sealants, glues, hemostats, sutures, tapes and other wound closure technologies.

See the full report description and table of contents at http://www.mediligence.com/rpt/rpt-s145.htm.

Worldwide Surgical Sealants, Glues and Wound Closure 2007 may be purchased here.

Tags: medtech, hemostats, sealants

See complete MMD report listing here.

Bone Grafts/Substitutes, Polymers, Ceramics, Growth Factors and Tissue Engineering in Orthopedics

Fri, 20 Apr 2007 07:42:22 -0700

The use of products collectively known as "orthopedic biomaterials" represents a growing share of clinical practice in orthopedics. Current uses, products on the market, new products under development and their sales in the worldwide market are detailed in a MedMarket Diligence report that reveals opportunities for competitors.

See the full report description and table of contents at http://www.mediligence.com/rpt/rpt-m625.htm.

Worldwide Orthopedic Biomaterials 2007 may be purchased here.

Tags: medtech, orthopedics, biomaterials

See complete MMD report listing here.

Orthopedic Biomaterials: Products, Companies and Global Markets

Wed, 6 Dec 2006 07:25:53 -0800

A new MMD report details the current and emerging products and technologies in the global market for orthopedic biomaterials. Bone graft, bone substitutes, polymers, ceramics, bone growth factors, sealants/glues, anti-adhesion, tissue engineering and other products comprise this current $5 billion market worldwide.

The activities of 70 companies in this market are analyzed: Aastrom Biosciences, Inc., Absorbable Polymer International, Acologix Inc., Advanced Cell Technology Inc., Allograft Tissue Systems Inc (ATSI), Allosource, Alphatec Spine, Inc., Altiva Corporation, Amedica Corporation, Angstrom Medica Inc., ApaTech Ltd., Arthrex, Arthrotek, Artimplant, Berkeley Advanced Biomaterials Inc., Biocoat Inc., Biocomposites Ltd, Biocoral, Inc., BioMimetic Therapeutics Inc., Biopharm GmbH, BioSyntech Inc., CeramTec AG, CeraPedics LLC, Clearant Inc., Closure Medical Corporation, Cortek, Inc., Cryolife, Inc., De Puy Inc., Encelle Inc., Encore Medical, Enobia Pharma Inc., Etex Corporation., Fidia Advanced Biopolymers s.r.l., FzioMed Inc., Genzyme Biosurgery, Inc., Haemacure Corporation, Inion Ltd, Integra Lifesciences Holdings Corporation, Interpore Cross International, Invibio Material Solutions, Isotis, N.V., Isto Technologies Inc., Japan Medical Materials Corporation, LifeCell Corp., LifeNet Allografts, Medtronic Sofamor Danek, Metoxit AG, Morgan Advanced Ceramics, NovaBone Products LLC, Ortec International, Inc., OrthoLogic Corporation, Orthovita, Inc., Osiris Therapeutics Inc., OsteoBiologics Inc, Osteohealth Company, Osteotech, Inc., Protein Polymer Technologies Inc., Regen Biologics, Inc., Regeneration Technologies, Inc., Smith & Nephew, plc., Stryker Biotech, Synthes, Inc., TEI Biosciences, Teknimed SA, Tutogen Medical, Inc., Wright Medical Technology, Inc.

See the full report description and table of contents at www.mediligence.com.

Worldwide Orthopedic Biomaterials 2007 may be purchased here.

Tags: medtech, orthopedics, biomaterials

See complete MMD report listing here.

Worldwide Market for Orthopedic Biomaterials (Report): Products, Markets, Shares and Outlook Globally (from MMD)

Wed, 6 Dec 2006 07:53:51 -0800

The orthopedic biomaterials market is an evolving arena in the development, adoption and/or evolving use of bone, bone substitutes, polymers, ceramics, bone growth factors, sealants/glues, anti-adhesion, tissue engineering and other products. The market is party to established orthopedic device manufacturers as well as niche biomaterials companies with innovative offerings. The resulting $5 billion current orthopedic biomaterials market will grow at double digit annual rates reaching nearly $10 billion by 2011. MedMarket Diligence has completed a global report on products, technologies, markets and players, with insights on the market's outlook.

The report description and table of contents may be viewed here.

Worldwide Orthopedic Biomaterials 2007 may be purchased here.

Tags: medtech, orthopedics, biomaterials

See complete MMD report listing here.

Refractive Surgery, Cataract Surgery, Glaucoma Treatment, Other Ophthalmic Markets Detailed in Global Report from MMD

Mon, 4 Dec 2006 07:42:56 -0800

The products, technologies, markets and companies in the field of vision diagnostics, eye care products, cataract surgery, refractive surgery, glaucoma treatment, and treatment for back of the eye disorders are analyzed by sector and geographic segmentation in a new report from MMD (MedMarket Diligence).

Companies covered include: Acufocus, Addition Technology, Inc., Advanced Cell Tech, Inc., American Optisurgical, Inc. (AOI), Aquasys, Inc, BD Medical Ophthalmic, Biosyntrx, Inc., Calhoun Vision, CustomVis, Eagle Vision, Eli Lilly, Endo Optiks, Inc., Escalon Medical Imaging, EyeKon Medical, Eyemaginations, Eyeonics, Inc., EyeSys Vision, Inc., FCI Ophthalmics, Genentech, Geuder AG, Glaukos, Haag-Streit, Heidelberg Engineering, Inc., Heine, Howard Instruments, Huvitz, IOP, Inc., IRIDEX, iScience Interventional, ISTA Pharmaceuticals, Keeler Instruments, Kowa Optimed, Lacrimedics, Leica Microsystems, Lenstec Inc, Lumenis, MacuScope, MacuSight, Inc., Marco, Mastel Precision, Medennium, Micro Medical Devices, Inc, Moeller-Wedel., MST, Neitz Instruments Co, NeoMedix, NeoVista, New World Medical, Nidek, Inc., Novadaq Technologies, Novartis Ophthalmics, NovaVision Inc., OASIS Medical, OccuLogix, OculusGen Biomedical, Odyssey Medical, Omni Lens, Ophtec, Optikon 2000 s.p.a., Optimedica, Optos, Inc., Optovue., Pelion Surgical, Pfizer Ophthalmics, Quest Medical, Refractec, Reichert, Regeneron Pharmaceuticals, Rhein Medical, Santen, Inc., Scan Optics, Schwind Eye-tech Solutions, ScyFIX, Second Sight, Sirion Holdings, Inc. (formerly Sirion Therapeutics), Sonogage, Sonomed., Stereo Optical Company, Inc., STAAR Surgical, Surmodics, Synemed, Tekia, Titan Surgical, Tomey, Topcon Medical Systems (TMS), Tracey Technologies, Trevi Technology, Visiogen, Inc., Vistakon, Vistakon Pharmaceuticals, LLC, Visual Pathways, WaveLight AG, Welch Allyn, Woodlyn, Inc., and Ziemer Ophthalmic Systems AG.

Ophthalmology 2007 may be purchased here.

Tags: medtech, ophthalmology, refractive, cataract, lasik

See complete MMD report listing here.

Worldwide Ophthalmology Report from MedMarket Diligence, LLC

Fri, 10 Nov 2006 14:40:57 -0800

Worldwide Ophthalmology Market 2007
MedMarket Diligence has completed a worldwide analysis of the market for devices, drug and diagnostic instrumentation in ophthalmology. The report details the products, technologies, companies and markets per country and/or region for individual western European countries (UK, Germany, France, BeNeLux, Italy and Spain), Japan and other key international markets; Asia (India, Korea, Australia, Russia and China), the Americas (Canada, Mexico, Brazil) and Middle East and Africa categories.

The report is described with a detailed table of contents and list of exhibits here. The report is available for purchase online here.

Tags: medtech, ophthalmology

The $37 Billion Diabetes Device Market of 2010 (from MedMarkets)

Thu, 2 Nov 2006 10:43:26 -0800

In many developed countries, including the United States, the increase in diabetes prevalence is reaching epidemic proportions. Roughly 250 million patients worldwide are now estimated to have the disorder, a number that is expected to rise to 350 million by 2025.  The products, technologies and companies active in the market for diabetes management products are detailed in the October 2006 issue of MedMarkets, and a 2006 report, from MMD.

See coverage in the October issue of MedMarkets.  See the MedMarket Diligence report on the Worldwide Diabetes Management Market.

Subscribe online to MedMarkets.  Or sign up for a three month trial.

Tags: diabetes, medtech, glucose

Micro- and Nanomedicine 2006 Report by MMD Praised by Nanotechnology.com Founder

Mon, 9 Oct 2006 06:46:48 -0700

MedMarket Diligence's report on Micro- and Nanomedicine was praised by nanotech investment expert, Darrell Brookstein, who found the report's "analytical work to be exceptional." The founder of The Nanotech Company, LLC, and Nanotechnology.com, Mr. Brookstein writes on and tracks developments in the nanotechnology field.

Below is an excerpt from Mr. Brookstein's Oct. 3 message to his "Best of NanoWeek" subscribers:

Dear Best of the NanoWeek Subscriber,

...

MedMarket Diligence has completed a worldwide business analysis of medically-applied nanotechnologies and MEMS (http://www.mediligence.com/rpt-t625.htm). The report, written for decision-makers in the medical product and investment industries, details the status of technology development, product introduction and actual market penetration of diagnostic and therapeutic applications employing technologies at the micro- and nanoscale. The report applies seasoned industry analysis that is grounded in reality, not hype. The report identifies, describes and focuses in on 100 key companies and details their specific efforts in nanomedicine. The report is a critical resource for participants, investors and others with a stake in micro- and nanomedical product markets. Click here for a complete description of the report and its table of contents: http://www.mediligence.com/rpt-t625.htm.

Folks at my companies, The Nanotech Company, LLC and Nanotechnology.com, find the analytical work to be exceptional and we are already deriving value from its use. I can highly recommend it to anyone who is serious about the field: scientist, entrepreneur, executive or investor.

...

Thanks.

Best regards,

Darrell Brookstein

Tags: nanotech, nanotechnology, MEMS, nanomedicine

Medical Technologies on the Leading Clinical Edge -- Insights into Emerging Market Medical Opportunities

Thu, 5 Oct 2006 08:01:47 -0700

The most significant developments affecting current and future medical technology markets are revealed at a point that MedMarket Diligence (MMD) calls the "Leading Clinical Edge". Here, the most important clinical trial results emerge, , specific new technologies are evaluated, clinicians explore new techniques and other developments occur that have the potential to dramatically expand, overturn or create medical technology markets. "Leading Clinical Edge" is a regular feature of MedMarkets, from MMD.

Tags: medtech, implant, medical device, medical technology

Medical Technology Market Outlook for 2007: A Survey by MedMarket Diligence, LLC

Mon, 2 Oct 2006 13:31:28 -0700

The outlook for commercial success in medical technologies in 2007 will be different for different market players. MedMarket Diligence is conducting a brief (5-10 minute) survey of market participants to identify the factors expected to affect this commercial success.

Click here to take the survey.

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes the MedMarkets newsletter, a monthly analysis of the market implications of new medical technologies, and dedicated reports on technology markets. For additional details, contact Patrick Driscoll at email or call 949-859-3401 or toll-free (in the U.S.). 1-866-820-1357.

Tags: medtech, implant, medical device, FDA, medical technology

Markets for Surgical Devices for Tumor Ablation (MedMarkets)

Mon, 25 Sep 2006 15:02:28 -0700

Use of ablation technologies for tumor treatment is growing at>25% annual rates, particularly for cryotherapy and radiofrequency ablation, with prostate cancer and liver cancer among the most common applications, according to the September 2006 issue of MedMarkets, from MedMarket Diligence.

See more details in MedMarkets.

-----------
See also the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, ablation, cryotherapy, RF ablation.

Sample Content from Medical Technology Reports - New XML/RSS Feed

Tue, 5 Sep 2006 14:58:50 -0700

New sample content from MedMarket Diligence's Market and Technology reports will be routinely posted and made accessible at a new rss/xml feed at this link.

-----------
See the comprehensive list of MedMarket Diligence Reports.

Tags: medtech

Ablation and Other Energy-Based Devices in General Surgery (coverage in MedMarkets)

Fri, 18 Aug 2006 14:07:37 -0700

The dynamic market for energy-based devices used in general surgery is growing steadily with short term annual growth rates of 12%, according to the August 2006 issue of MedMarkets from MedMarket Diligence. Consolidation and innovation are two recent industry trends.

See more details in MedMarkets.

-----------
See also the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, biomaterials, orthopedics

MedMarket Outlook: Medical Devices in a Future Scenario

Thu, 17 Aug 2006 10:48:46 -0700

(from August 2006 MedMarkets)

The future of medtech is proceeding along paths determined by technologies already developed, but also guided by the need to provide less invasive treatment of disease with better long-term outcomes. If these paths are followed to their logical endpoint, medical technologies of the future can be predicted. Concurrently, paths toward the development of treatments via biotechnology have their own logical endpoints. Many biotechnologies have the potential to preempt medical technologies, due to their intrinsic design as "rational therapeutics" -- treatments of the root cause of disease rather than only its symptoms.

Here we consider the development in medical technology to have largely achieved its potential and we describe the devices and their characteristics as they would exist in such a future. We make no assertion that each and every technological hurdle that needs to be crossed can indeed be crossed (we imply the possibility); we simply give the benefit of doubt to the technologies that may be developed in order to consider what benefits may ensue.

In short, the future of medtech will be such that two general categories of technologies exist; those that are focused on treating specific pathologies and symptoms and those that represent organs or organ systems. Lastly, it should be noted that we envision this "future scenario" not as one happening 25 years (or more) hence, but in some cases less than a decade.

Disease- and Trauma-Specific Device Solutions
In the idealized future medtech industry, medical devices will have been optimized to facilitate the body's own capacity to heal. Devices will be constructed to provide the function -- e.g., maintaining the patency of a vessel lumen (stents), serving as a temporary or permanent lumen (AAA graft), be a fully functioning hip replacement, etc. -- as long as (and no longer than) necessary for the body to complete all of the repairs of its own that are possible. In this sense, devices will be developed to help the body help itself, then get out of the way to not impede further healing. In particular, bioresorption will have become highly sensitive to timing (stents will dissolve or deconstruct to be excreted at the precise time needed). This will include extracellular matrices used for the regeneration of tissues of all types of tissue (muscle, bone, even nerve) with the matrix facilitating tissue ingrowth before being resorbed. Similarly, biocompatibility will become a more active feature of implanted devices such that they will go well beyond simply being inert or inducing no immunological or other response and will at a maximum, will elute drugs, proteins or other agents that will actively stimulate or facilitate the body's normal healing process.

Devices will be highly intelligent, sensing the conditions in their environment and responding as necessary. Responses will include bioresorption, release of drugs, change in shape or other responses

Devices will be tracked wirelessly for status, providing patient and clinician with information about the status of healing, alerting each to changes requiring intervention long before adverse symptoms appear. This tracking will also include tracking of the device itself, revealing data on device integrity and alerting the patient/clinician to any change.

Increasingly complex devices will be implanted percutaneously, endoscopically or by other means to minimize any trauma. During implantation, the devices will have very low profiles to enable them to traverse to the target site through very small and/or sensitive (e.g., enervated) tissues.

Cost will have played a critical role in determining the effectiveness of device development, but not simply considering the device cost itself, which may be significant. The true cost of these devices will be determined thoroughly as a measure of their ability to achieve specific outcomes compared to the costs of any and all technologies or approaches that compete for similar outcomes.

These device technologies are based on the premise of technologies under development now. Advances in materials technologies, drug/device innovations and many others may produce opportunities for devices with benefits largely unforeseen at this time.

Biohybrid, artificial organs
In light of medtech's general inability to compete directly with the premise of biotech -- treatment of root disease rather than symptoms, medtech will have the potential nonetheless to provide solutions to disease and trauma, with the solutions being ones in which medtech devices or systems so thoroughly address the symptoms of diseases as to emulate cures of them.

In the future world we are envisioning, many organs and organ systems will be available to replace or augment the functions of organs that have been removed or are dysfunctional as a result of disease or trauma. The organs will be comprised of mechanical and biological components that will variously house reservoirs of therapeutics that will periodically and painlessly be replenished, contain bioreactors that will express patient-specific proteins, hormones and other naturally occurring substance, or provide other therapeutic intervention (as with defibrillators, pacemakers, etc.). Mechanical components will be made of materials producing no inflammatory response, inducing no clot formation or other effect and will otherwise be completely neutral to the body.

These organ systems, like the devices described above, will be intelligent, sensing multiple parameters and responding in real-time basis to maintain ideal homeostatic control specific to the patient's dynamic needs (sleep, stress, exercise, metabolism, etc.). The "intelligence" of the systems will be represented in ways from the simple, including elution based on the concentration of substances (platelets, specific proteins, etc.) in the environment (such as to prevent restenosis), to the complex, including microprocessor-calculated basal or bolus infusion of drug or other substance based on biofeedback-mediated function (e.g., insulin pump and glucose monitor).

The status of the biohybrid organ/system will be monitored remotely by the patient and, in turn, by the physician through wireless communication to display current patient condition, trended functions and other status. Eventually, such external monitoring will become unnecessary other than for unusual events, such as extreme changes in patient condition that, even though the organ/system may be well prepared to respond to, warrants attention by the patient and/or clinician.

The biohybrid organ/system status will also be communicated wirelessly, displaying data on its sensor functions, reservoir levels or other parameters of its function, as well as the system's integrity. As with monitoring the organ/system's environment (noted in previous paragraph), the monitoring of the organ/system itself will eventually be silent other than for unusual or adverse events signalling a problem with the system itself.

The power sources employed by these systems will have evolved from being extremely long-term batteries that only infrequently require recharging (done remotely) to motion-activated power (or similar alternative energy sources) to potentially biological sources deriving power from the patient, such as (in a very advanced scenario) through exploitation of energy from adenosine triphosphate (ATP).

Examples of the organs or organ systems that may ultimately be developed (and are in process) include the following:

Pancreas - Glycemic control will be ensured through basal infusion of insulin and periodic bolus matching fluctuating needs. [Based on developments by: Medtronic Minimed, Inc., Smiths Medical MD, etc.]
Heart - Effective replacement of normal heart function will be achieved through designs and construction that will produce no hemolysis, and produce cardiac output precisely matching circulatory need. [Based on developments by: ABIOMED, Inc. Jarvik Heart, Inc., SynCardia Systems, Inc.]
Lung - An artificial lung will largely be achieved through the development of highly effective materials that virtually mimic alveolar epithelium at the interface between lung and blood vessels, enabling efficient gaseous exchange. [Based on developments by MC3, Inc. Novalung GmbH. ALung Technologies, Inc.]
Liver - The myriad functions of the liver will have made it one of the most difficult organs to replace, in effect demanding the development of a master organ with multiple separate organ components addressing the needs of homeostasis (proteins, fat/cholesterol, hormones, vitamins, glucose, etc.), synthesis (proteins, bile acids, cholesterol), storage, excretion, filtering and defensive barrier against bacteria in the gut. The development of biofeedback and control across such multiple areas will be a herculean accomplishment. [Based on developments by Daji Biosciences, Inc. Polygenetics, Inc.]
Kidney - Filtration and regulation of water and inorganic electrolytes in the artifical kidney, by comparison to the development of the artificial liver, will be considerably less challenging. [Based on widespread developments of renal dialysis.]
Skin/integumentary - As an organ system, the integumentary serves an extremely important one in its defense against infection. Artificial integumentary systems may well be developed, although tissue engineering technologies are likely to soon eclipse any artificial technologies.
Limbs - The necessary development of biomechanics and systems to enable autonomic and conscious neural control of limbs may ultimately only be limitated by the strength the patient's healthy anatomy to which it is joined. Fine-motor skills will likely be indistinguishable from biological limbs. Sensitivity to heat and pressure may even be regulated to maximize tolerance of the environment such that performance will exceed that of normal limbs. Overall appearance and in detail will be indistinguishible from normal limbs. [Fundamental technology already widely available; development will continue toward improving the performance and appearance of artificial limbs.]

Selected companies pursuing artificial organ or related development:

3DM, Inc. – Cambridge, MA; http://puramatrix.com
ABIOMED, Inc. – Danvers, MA; http://abiomed.com
ALung Technologies, Inc. Pittsburgh, PA; http://alung.com
Boston Scientific Corporation – Natick, MA; http://bsci.com
Daji Biosciences, Inc. – Graham, NC; no URL
HepaLife Technologies, Inc. – Vancouver, Canada; http://hepalife.com
Jarvik Heart, Inc. – New York, NY; http://jarvikheart.com
Johnson and Johnson -- New Brunswick, NJ; http://jnj.com
MC3, Inc. – Ann Arbor, MI; http://mc3corp.com
Medtronic, Inc. – Minneapolis, MN; http://medtronic.com
MicroCHIPS, Inc. – Bedford, MA; http://mchips.com
Novalung GmbH – Hechingen, Germany; http://novalung.com
Polygenetics, Inc. – Los Gatos, CA; http://polygenetics.com
Smiths Medical MD, Inc. – St. Paul, MN; http://delteccozmo.com
SynCardia Systems, Inc. – Tucson, AZ; http://syncardia.com
VeriChip Corp. – Delray Beach, FL; http://verichipcorp.com

To varying degrees, these developments are already on their way toward completion. And while, indeed, many hurdles remain before some of these scenarios will be possible, one must consider these hurdles in comparison to the hurdles faced by the biotechnology industry as it pursues solutions a variety of diseases and disorders. The "rational therapeutic" holy grail is one that has for biotech been a source of endless promise and endless solicitation of additional venture capital. But as "imperfect" as some of the medtech solutions above may be, their potential as self-contained, cure-like solutions for disease make them eminently more promising for their near-term potential than do "perfect" biotech solutions.

Tags: medtech, biomaterials, orthopedics

----------------------------------------------------------
See MedMarket Diligence Reports: Nanomedicine, Diabetes, Startups 2006, Virtual Reality, Wound Managment, Surgical Sealants

Orthopedic Growth From Biomaterials

Wed, 16 Aug 2006 08:05:36 -0700

The market for orthopedic devices and materials stood at $20 billion worldwide in 2005. Some of its biggest growth is now coming from orthopedic biomaterials, a diverse group of products including grafts, polymers, growth factors, ceramics, tissue engineering products, surgical sealants/glues/hemostats and others. The August 2006 issue of MedMarkets details the products, competitors and market forecast for orthopedic biomaterials.

See more details in MedMarkets.

-----------
See also the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, biomaterials, orthopedics

'Leading Clinical Edge' Feature in MedMarkets Shows Medtech Horizon

Thu, 6 Jul 2006 15:12:49 -0700

"Leading Clinical Edge", a regular feature in MedMarkets from MedMarket Diligence, keeps medtech companies abreast of changes in clinical practice impacting the potential for current and emerging medical technologies. "Leading Clinical Edge" draws upon peer-review journals, clinical trials and other sources to reveal significant changes in the delivery of healthcare that open up opportunities -- and challenges -- for manufacturers .

See more details in MedMarkets.

-----------
See also the comprehensive list of MedMarket Diligence Reports.

Tags: medtech

Emerging Trends, Technologies and Worldwide Opportunities in Diabetes Market Detailed in 2006 Report from MMD, LLC

Wed, 5 Jul 2006 07:47:03 -0700

Worldwide diabetes market analyzed in report from MMD, LLC.

The diabetes market, which includes both pharmaceuticals and medical devices, is large, and is growing steadily for many reasons. First, the prevalence of diabetes is increasing, particularly that of type 2 in developed countries and those with increasing prosperity. Type 1 diabetes is also increasing, though less dramatically. Second, type 2 diabetes is responsive to drug therapy, and there is a continuing search for newer, better pharmacological agents. Third, insulin, required for all cases of type 1 and some of type 2 diabetes, poses administration problems, offering opportunities for new delivery systems. Fourth, patients with diabetes must monitor their condition by frequently checking the level of glucose in their blood, and there are ongoing attempts to make this process easier and more user-friendly by developing more advanced (and expensive) devices.

A fifth driving factor in the diabetes marketplace is the search for a fundamentally better way to manage the disease. Some options are mainly surgical – transplants of pancreatic cells, for example. Another focus for research is to combine glucose monitoring with insulin administration in a self-controlled wearable device. And farther in the future are prospects for using stem cells to grow new beta cells, and for using genetic knockout techniques to block the metabolic processes that cause diabetes.

__________________________

Other recent Reports from MMD, LLC:

Micro- and Nanomedicine

Startups 2006

See also MedMarkets and the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, diabetes

Drug Delivery Markets to Get Huge Boost from Nanotechnology and MEMS, Details MMD Report

Sat, 1 Jul 2006 06:51:31 -0700

According to a new report from MedMarket Diligence, over 150 companies are active in the field of drug delivery, and a large portion of them are seeking technologies that will result in improved specificity and reduced dose-induced toxicity, which makes the upside for nanotechnology and MEMS in drug delivery an opportunity measured in double-digit growth rates.
__________________________

See also MedMarkets and the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, nanotech, MEMS, drug delivery

Nanotech and MEMS in Medical Applications: Comprehensive Market and Technology Report Released from MedMarket Diligence

Sun, 28 May 2006 10:36:08 -0700

The most extraordinary possibilities of nanotechnology and MEMS (microelectromechanical systems) remain to be developed, yet a $billion+ market already exists for these technologies in biomedical applications, spanning cancer treatment, drug delivery, wound management, sensor technologies, pacemakers, molecular diagnostics, hearing aids and others. The current markets, the current status of development and the emerging and potential markets worldwide are detailed in a new report from MedMarket Diligence.
__________________________

See also MedMarkets and the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, nanotech, MEMS

Nanomedicine Shakes Off Hype, Coverage in May 2006 MedMarkets and New Report from MMD (MedMarket Diligence)

Wed, 17 May 2006 11:57:17 -0700

The potential for nanomedicine, the medical application of nanotechnology, is vast, and has been touted as such almost endlessly since it was conceived. However, already on the market in the U.S. are wound dressings that exploit the antimicrobial properties of nanocrystalline silver, while nanotech-based products for drug delivery, materials technologies and other nanomedical applications are indeed real and in clinical trials now. These findings are presented in the May 2006 issue of MedMarkets, and a forthcoming report from MedMarket Diligence.

__________________________

See "Micro- and Nanomedicine: Technologies, Applications, Industry, and Markets Worldwide", report #T625 (May 2006) detailed here.

See also MedMarkets and the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, nanotech, MEMS

New Competitors in Drug-Eluting Stent Market Seeking to Wrest Share from Boston Scientific, Cordis/J&J, According to April MedMarkets

Tue, 2 May 2006 16:41:08 -0700

The $6 billion global market for drug-eluting stents is poised for new competition from players seeking to tap into a market first dominated by Cordis/J&J and now split by Cordis/J&J and Boston Scientific.

Also in the April issue of MedMarkets, we address critical developments -- product milestones, investment growth, and other key market data -- in the newly optimistic biotech market.

Plus, Startups, Early Stage Companies, Developments, Leading Clinical Edge and other coverage.

__________________________

See also the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, stents, drug-eluting

White Paper: High Growth Medical Technologies

Wed, 23 Aug 2006 15:34:58 -0700

MedMarket Diligence (MMD) has updated a white paper on select high growth medical technologies based on research across multiple technologies and clinical applications through the company's syndicated Reports business and MedMarkets newsletter.

The paper is also noted at http://medmarkets.blogspot.com/.
__________________________
See also the comprehensive list of MedMarket Diligence Reports.

Tags: medtech

Emerging Technologies and Worldwide Markets in Diabetes Management

Wed, 22 Mar 2006 14:12:20 -0700

According to a new report from MedMarket Diligence (MMD), diabetes management is facing the emergence of multiple new technologies, from marginal improvement (lancing devices, continuous monitoring, new insulin and antidiabetic drug formulations) to radical shifts (optical glucose sensors, closed-loop monitor/pump systems, stem cells, artificial pancreas). A large marketplace with many competitors and sectors serve the needs of a growing patient population as the large, undiagnosed Type 2 population is steadily penetrated and as other forces (e.g., obesity) continue to drive incidence upward.

__________________________

See also the comprehensive list of MedMarket Diligence Reports.

Tags: medtech, diabetes, glucose, insulin

Intracranial Endovascular Coils and Microstents, Product Introductions Priming a Growth Market, According to March MedMarkets, from MMD

Fri, 17 Mar 2006 12:05:02 -0700

The market for intracranial endovascular coils and microstents is poised for explosive growth with several new devices being launched within the past few months and several others currently in clinical trials, according to MedMarkets from MedMarket Diligence (MMD).

__________________________

March 2006 coverage in MedMarkets.

See the comprehensive list of MedMarket Diligence Reports.

Applications of Tissue Engineering in Urology - March 2006 MedMarkets

Fri, 17 Mar 2006 11:56:29 -0700

Stress urinary incontinence (UI) and kidney failure, as candidate applications of tissue engineering, are examined in the March 2006 issue of MedMarkets and a market and a technology report from MedMarket Diligence.

_________________________

See coverage in the March 2006 MedMarkets issue.

See also a list of MedMarket Diligence Reports.

Advanced Wound Management Product Usage Increasing Globally and Especially in Select Regional Markets (U.S., Europe, Japan) - Report

Fri, 17 Mar 2006 10:19:01 -0700

Globally, the market for the diverse array of products in surgical, chronic and acute wound management stands at $13 billion, with aggregate growth at 7% annually. Select sectors are demonstrating appreciably stronger growth including active physical stimulation, pharmaceuticals, enzymatic debriders, tissue engineering, and other active therapies for wound management. Differences geographically in the clinical management of wounds and in the adoption of new products are also creating opportunities in local markets. These data are detailed in the newest report by MedMarket Diligence on the worldwide wound management market.

__________________________

See also the comprehensive list of MedMarket Diligence Reports.

Biological Valve Technologies, Minimally Invasive Techniques Bolster Heart Valve Market; High Growth in Sealants, Glues and Anti-Adhesion Market, According to February 2006 MedMarkets

Tue, 21 Feb 2006 08:40:21 -0700

Biological and mechanical heart valves compete in the $1+ billion worldwide market for the treatment of heart valve disease. Products, technologies, competitors and trends detailed in the February 2006 issue of MedMarkets. Also provided is an update on the products, technologies and companies in the markets for surgical sealants, high strength glues and prevention of post-surgical adhesions.

__________________________

February 2006 coverage in MedMarkets.

See also the comprehensive list of MedMarket Diligence Reports.

Bone Graft Use in Europe and the U.S. Dominated by Spine Fusions

Thu, 19 Jan 2006 08:21:45 -0700

With application in many types of orthopedic surgery, the primary application for bone grafts and bone graft substitutes is spine surgery, which accounts for nearly half of all types of bone graft utilization. This is true in both the United States and Western Europe. Details in the January 2006 issue of MedMarkets.

__________________________

January 2006 coverage in MedMarkets.

See Bone Graft Substitutes report details and Spine Surgery Worldwide report details.

See also the comprehensive list of MedMarket Diligence Reports.

U.S. and Western European Bone Graft Substitutes Markets

Thu, 5 Jan 2006 13:45:29 -0700

The markets for bone graft substitutes, one of the more robust growth sectors in orthopaedics, is covered in a report now available from MedMarket Diligence. The U.S. and Western European Bone Graft Substitutes Market report is expected to sustain double digit growth into the next decade.

Coverage in the report includes the detail in the three major segments of the bone graft substitute market: synthetic bone graft substitutes, demineralised bone matrices (DBMs) and bone morphogenic proteins (BMPs), and data is provided on products, markets and competitors in the U.S. and the major countries of Western Europe.

__________________________

See Bone Graft Substitutes report details.

See also a list of MedMarket Diligence Reports.

Nanomedicine: Small World, Vast Possibilities

Sat, 31 Dec 2005 07:35:24 -0700

Applications of nanotechnology have already been integrated into diagnostic and therapeutic devices. There is intense commercial interest in the medical uses of nanotechnology with at least 100 companies actively involved in this field. The December 2005 issue of MedMarkets details the status of the technologies, products and applications being developed by specific companies.

Subscriber access.

__________________________

See December 2005 MedMarkets.

See also a list of MedMarket Diligence Reports.

Global Analysis of Diabetes Management Market, 2005-2015

Tue, 13 Dec 2005 07:35:24 -0700

MedMarket Diligence, a highly regarded source of data and insight in medtech markets, has analyzed the $25 billion market for drugs/medications, devices, diagnostics, therapeutics and their combinations in the management of diabetes, with data and insights provided on worldwide and geographic segmentation. The analysis reveals high growth opportunities for manufacturers.

__________________________

See Diabetes report details.

See also a list of other MedMarket Diligence Reports.

Virtual Reality Applications in Surgery and Imaging: Technology and Market Forecast

Fri, 9 Dec 2005 09:49:43 -0700

The global computer-aided surgery market is approximately $465 million and growing rapidly. In the U.S., the computer-aided surgery market was an estimated $296M in 2004. As new companies enter this arena, the annual growth rate is expected to increase from its current level of approximately 10% in 2005 to more than 20% in 2009. The anticipated compound annual growth rate over the forecast period is nearly 16%. While currently systems are primarily used in neurosurgery, developments in surgical navigation systems will facilitate computer-aided surgical systems in other surgical specialties. Chief among these are orthopedics, otolaryngology, cardiac, and spinal surgery. As the technology matures, computer-aided surgery is expected to become standard practice in many specialties, with concomitant improvement in return on investment for hospitals and surgery centers.

The current product offerings, products under development, and their status, are detailed in the U.S. market assessment from MedMarket Diligence covering virtual reality systems targeted to surgery and imaging application.

__________________________

See Virtual Reality report details.

See also a list of other MedMarket Diligence Reports.

Embolic Protection: Trials, Products and Markets (in November 2005 MedMarkets)

Mon, 28 Nov 2005 09:47:32 -0700

The $1 billion unrealized market for embolic protection is progressively being realized. Trials have demonstrated the needed outcomes and competitors are gaining approvals with products for patients at high risk of stroke.

The clinical trials, product developments and competitor moves in the embolic protection market are reviewed in the November 2005 issue of MedMarkets, from MedMarket Diligence.

See coverage in past issues of MedMarkets.
__________________________

See a list of MedMarket Diligence Reports.

Drug-Eluting Stents: Off-Label Usage, Competitor Moves

Mon, 28 Nov 2005 09:47:32 -0700

Recent data from the 2005 TCT meeting further reveal the nuances in specific clinical indications favoring different drug-eluting stents (DES). The market continues to evolve nonetheless, with developments from a list of robust competitors.

Clinical trials, product developments and competitor moves are reviewed in the November 2005 issue of MedMarkets, from MedMarket Diligence.

See coverage in past issues of MedMarkets.
__________________________

See a list of MedMarket Diligence Reports.

Computer-Aided Surgery: Products, Applications and Markets for Virtual Reality in U.S. Markets

Mon, 17 Oct 2005 11:37:06 -0700

Novel Devices for the Treatment of Spinal Disc Disease

Mon, 17 Oct 2005 11:37:06 -0700

Advancements in intraoperative tools, devices and techniques have facilitated minimally invasive surgical approaches to the treatment of spinal disc disease, substantially reducing hospitalization time and improving patient outcomes.

The spinal disc disease treatment market is covered in the October issue of MedMarkets from MedMarket Diligence. The market for spine surgery devices is also covered in the detailed MedMarket Diligence spine surgery report.

*****************************
See coverage in past issues of MedMarkets. Click to subscribe online or via subscription card.

Growing Market for Obesity Surgical Devices

Mon, 17 Oct 2005 10:38:13 -0700

The rising prevalence of obesity and the lack of significant change in the trend despite the drumbeat of attention on obesity in the press has supported steady growth in the number of gastric bypass and other surgical treatments for obesity. The worldwide market for these obesity surgical devices will grow to over $700 million by 2013.

The obesity treatment device market is covered in the October issue of MedMarkets from MedMarket Diligence. The market for obesity devices is also covered in the detailed MedMarket Diligence worldwide obesity report.

*****************************
See coverage in past issues of MedMarkets. Click to subscribe online or via subscription card.

Growth in Formation of Medtech Startups, Over 100 Startup Medical Technology Companies Identified in 2005

Wed, 12 Oct 2005 07:56:15 -0700

The number and type of new companies founded in the past 12 months is an encouraging indicator of the growing confidence of entrepreneurs in the medical technology industry. Sample of technologies from startup medtech companies identified in MedMarkets from MedMarket Diligence.

See coverage in past issues. Click to subscribe online or via subscription card.